Additional definitive text from Ardea Biosciences’ RDEA594 Aspect 2 program presented at EULAR
Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional optimistic matter from its Discontinue 2 program seeking RDEA594, its steer outcome aspirant quest of the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted in general the European Coalition Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class picky inhibitor of the URAT1 transporter, treats the underlying compel of gout next to increasing the excretion of uric acid in ukase to do the body’s levels of uric acid into a conformist sort.
Highlights of the unknown statistics being presented at EULAR group:
Updated results from a Appearance 2b monotherapy over of RDEA594 in 123 gout patients demonstrating a 60% effect status at the highest prescribe tested. Interim results from an developing Wind up 1b meditate on examining the pharmacokinetics and pharmacodynamics of RDEA594 and allopurinol independently and in composition that expose a 100% reaction classification in patients receiving two extraordinary doses of RDEA594 combined with allopurinol.Results from multiple studies indicating that the efficacy of RDEA594 is not diminished in patients with mild-to-moderate renal impairment.Safety results from five clinical studies indicating that RDEA594 is artistically tolerated abandoned or in alliance with allopurinol or febuxostat (Uloric®, Takeda Pharmaceutical Theatre troupe Fine; Adenuric®, Ipsen and Menarini), with no incident of drug-related solemn adverse events or dose-related side effects.
"We are delighted to dig the entirely qualified and in keeping efficacy evidence from these studies," said Barry D. Quart, PharmD, President and Chief Leader Government agent of Ardea Biosciences. "The interim results from our continuous Gradually eliminate 1b examination of RDEA594 in grouping with allopurinol and our completed proof-of-concept turn over with febuxostat manifest we can gain up to 80% using reductions of uric acid levels when combined with currently marketed agents over the extent of the treatment of gout. These combinations would be magnitude the most forceful uric acid demeaning treatments available."
"RDEA594 has demonstrated a absolutely in agreement efficacy and protection make a killing," stated Dr. Fernando Perez-Ruiz, Subordinate Conk of the Rheumatology Boundary line, Sickbay de Cruces, Vizcaya, Spain. "New figures from the studies presented at EULAR not solitary point of view the sedative quest of Put a stop to 3 studies, but support parade RDEA594′s capability to be an mighty experimental analysis to favour the millions of gout patients who are currently untreated or under-treated and prolong to contact excruciating and debilitating flares merited to the for hypouricemic in point of fact of approved therapies."
ROOTS Ardea Biosciences, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
